Trial Profile
Phase Ib of CC-5013 and Paclitaxel in Patients With Advanced Solid Tumors.
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Paclitaxel
- Indications Breast cancer; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Solid tumours
- Focus Adverse reactions
- 12 Sep 2011 Planned end date changed from 1 Dec 2011 to 1 Mar 2012 as reported by ClinicalTrials.gov.
- 12 Sep 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 12 Jul 2010 New trial record